AstraZeneca to buy France's Amolyt Pharma for £780m

AstraZeneca PLC (LSE:AZN) has agreed to buy France-based Amolyt Pharma for $1.05 billion (£780 million) to strengthen the late-stage drug pipeline of its Alexion rare disease arm. Lyon-based Amolyt's lead drug is called eneboparatide (AZP-3601), a treatment for hyperparathyroidism that is currently in Phase III trials. Hypoparathyroidism sufferers cannot generate enough of parathyroid hormone (PTH), resulting in significant dysregulation of calcium and phosphate, which can lead to chronic kidney disease and ...